CB-13
Aliases: Cra-13, Sab-378
Summary
CB-13 is designed to stay largely outside the blood–brain barrier, providing peripheral CB₁/CB₂ activity (analgesia, anti-inflammatory) with greatly reduced central psychoactivity. Recreational 'high' is weak or absent below very large doses; most user reports describe mild body relaxation, analgesia and sleepiness rather than classic cannabis effects. Because effective doses are hundreds of milligrams orally, material cost, impurities and liver load become significant concerns.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | - | - | - | 450mg+(notrecommended)+ |
| Vaporized | - | - | - | >50mg(littleadditionaleffect)+ |
Onset, Duration & After-effects
| ROA | Onset | Peak | Offset |
|---|---|---|---|
| Oral | 30-90 min | 2-4 hrs | 2-4 hrs |
Effect Profile
Scores (1–10) curated from multiple sources:
- Effect keyword matching from PsychonautWiki catalog
- Weighted by importance: core (×3), major (×2), minor (×1)
Moderate visuals with mild headspace and auditory effects, low body load
Tolerance
Tolerance Decay
Based on cannabinoid-class tolerance patterns: repeated daily activation downregulates CB1 signaling with partial reversal over days to weeks. Data specific to CB‑13 in humans are lacking; values above are heuristic. Evidence quality: anecdotal and cannabinoid-class extrapolation.
Cross-Tolerances
Effects
- Mild body euphoria/relaxation
- Analgesia
- Anxiolysis
- Sedation/drowsiness
- Dry mouth
- Nausea
- Reddened eyes
- Impaired coordination
- Mild hypotension/light-headedness
- Reduced heart rate
- Reduced anxiety
- Reduced physical symptoms of anxiety
- Decreased performance anxiety
- Euphoria
- Conceptual thinking
- Dizziness
- Anxiety
- Memory suppression
- Confusion
- Time distortion
- Tracers
- Color enhancement
- Tactile enhancement
- Increased music appreciation
- Enhanced tactile sensation
- Pattern recognition enhancement
- Warmth/tingling
- Dulled perception
- Drifting
- Auditory distortion